- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Prospective, Multicentre
- Study aim: To monitor the real-life effectiveness and safety of nirmatrelvir/ritonavir and molnupiravir for treating COVID-19
- Number of participants enrolled: 211
- Study enrolling from
- Study includes follow-up for 39 days
Study Data
- Adults
- Elderly
- General population
- Hospital wide
- Outpatient clinic
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Nirmatrelvir/Ritonavir
- Molnupiravir
External Links
Other information
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to